symptoms at an unacceptably bothersome level as reported by the patient, and judged by the examining clinician to be due to PsA based on ≥1 of the following: swollen joints, tender joints, dactylitis, enthesitis, axial disease, active skin and/or nail involvement, and extraarticular inflammatory manifestations such as uveitis or inflammatory bowel disease. † When there were no published studies, we relied on the clinical experience of the panelists, which was designated very-low-quality evidence. available low-quality evidence is inconclusive regarding the efficacy of OSMs in management of PsA, whereas there is moderatequality evidence of the benefits of TNFi biologics, in particular regarding their impact on the prevention of disease progression and joint damage. In making their recommendation, the panel recognized the cost implications, but put considerations of quality of evidence for benefit over other considerations. This guideline provides recommendations for early and